{"id":"W4322769118","doi":"10.1158/1538-7445.sabcs22-pd18-10","title":"Abstract PD18-10: Treatment of HER2-positive (HER2+) hormone-receptor positive (HR+) metastatic breast cancer (mBC) with the novel combination of zanidatamab, palbociclib, and fulvestrant","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital; Health Sciences Centre; Zymeworks (Canada); Sunnybrook Health Science Centre; Jewish General Hospital","funders":"","keywords":"Medicine; Fulvestrant; Palbociclib; Metastatic breast cancer; Trastuzumab; Tolerability; Internal medicine; Oncology; Pertuzumab; Combination therapy; Breast cancer; Cancer; Adverse effect; Estrogen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003717987,0.0006341925,0.0006264837,0.000267095,0.0001867963,0.0004878964,0.0006200298,0.0004204954,0.004548389],"category_scores_gemma":[0.0002478716,0.0001971762,0.0004240893,0.0002116731,0.0003123912,0.0004326307,0.0002593652,0.001479703,0.0007992964],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007756312,"about_ca_system_score_gemma":0.0009785715,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009965322,"about_ca_topic_score_gemma":0.002487886,"domain_scores_codex":[0.999881,0.00003591629,0.00001022419,0.00002284322,0.00001986612,0.00003009554],"domain_scores_gemma":[0.9998924,0.00001347645,0.00001994706,0.000007000602,0.00000989678,0.00005735757],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2210137,0.03324303,0.0131419,0.001690087,0.001218654,0.0009365163,0.0001803127,0.004973952,0.2374152,0.0007205688,0.01947545,0.4659907],"study_design_scores_gemma":[0.2585422,0.4936429,0.04419855,0.0001647063,0.001317116,0.003380215,0.0001288694,0.006091779,0.1363013,0.0005480008,0.05562024,0.00006407371],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9853838,0.004379358,0.001216821,0.0006109937,0.0001770616,0.00108438,0.002325704,0.0002396736,0.004582167],"genre_scores_gemma":[0.9871194,0.002438393,0.002110183,0.0004003745,0.0001079894,0.0004746657,0.003213667,0.00002339619,0.004111846],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004548389,"threshold_uncertainty_score":0.01521593,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05721189662845406,"score_gpt":0.3904071951522698,"score_spread":0.3331952985238158,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}